ReviewInternational journal of molecular sciences2023
Advances in Treatment of Dyslipidemia.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis.Endocrinology, diabetes & metabolism · 2026Pooled it
- Clinical and Biological Efficacy of Thai Herbal Blood Lipid-Lowering Formulation for Borderline Hyperlipidemia: A Double-Blind Multicenter Randomized Controlled Trial.Journal of evidence-based integrative medicineTrial
- Service delivery interventions for lipid testing and lipid-lowering therapy for primary and secondary prevention of cardiovascular disease in adults.The Cochrane database of systematic reviews · 2026Article
- Review
- Upper Arm to Upper Leg Length Ratio and Dyslipidemia: A Novel Application of a Fixed Skeletal Proportion Metric in a Nationally Representative U.S. Sample.International journal of environmental research and public health · 2026Article
- Article
- Predictive value of non-fasting apolipoprotein B/apolipoprotein A-1 ratio combined with systatin C for severe coronary artery stenosis in patients who undergo coronary angiography.Journal of cardiothoracic surgery · 2026Article
- Beyond conventional therapies: Gut microbiota modulation and macromolecular drugs in the battle against cardiometabolic diseases.Journal of pharmaceutical analysis · 2026Review
- Investigating Alternative Treatments for Dyslipidemia Using Bioactive Compounds Derived from Kiwifruit (Actinidia chinensis): A Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Analysis.Current drug targets · 2026Article
- Article
- A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part I.Life (Basel, Switzerland) · 2025Review
- Association of dietary inflammatory index with dyslipidemia and atherogenic indices in Iranian adults: a cross-sectional study from the PERSIAN dena cohort.Nutrition journal · 2025Article
- Correlation between dyslipidaemia and gastric cancer: pathogenesis to prevention and treatment strategies.Lipids in health and disease · 2025Review
- Comorbidity Patterns Among Patients Diagnosed with Sialolithiasis: A Retrospective Analysis.Journal of clinical medicine · 2025Article
- The Potential of Edible Bird's Nests in Reducing Cardiovascular Disease Risk Factors: A Narrative Review.International journal of molecular sciences · 2025Review
- Post-marketing quality assessment of some brands of rosuvastatin tablets available in Jos, North-Central Nigeria.BMC chemistry · 2025Article
- The Protective Effect ofFoods (Basel, Switzerland) · 2025Article
- The Role of the Planetary Diet in Managing Metabolic Syndrome and Cardiovascular Disease: A Narrative Review.Nutrients · 2025Review
- Nanotechnology and Artificial Intelligence in Dyslipidemia Management-Cardiovascular Disease: Advances, Challenges, and Future Perspectives.Journal of clinical medicine · 2025Review
- A prediction study on the occurrence risk of heart disease in older hypertensive patients based on machine learning.BMC geriatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks for the development and progression of cardiovascular diseases. These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). This review delves into the current treatment approach, focusing on equalizing these parameters while enhancing the overall quality of life for patients. Through an extensive analysis of clinical trials, we identify disorders that necessitate alternative treatment strategies, notably familial hypercholesterolemia. The primary objective of this review is to consolidate existing information concerning drugs with the potential to revolutionize dyslipidemia management significantly. Among these promising pharmaceuticals, we highlight alirocumab, bempedoic acid, antisense oligonucleotides, angiopoietin-like protein inhibitors, apolipoprotein C-III (APOC3) inhibitors, lomitapide, and cholesterol ester transfer protein (CETP) inhibitors. Our review demonstrates the pivotal roles played by each of these drugs in targeting specific parameters of lipid metabolism. We outline the future landscape of dyslipidemia treatment, envisaging a more tailored and effective therapeutic approach to address this widespread medical concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.